{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T22:52:58Z","timestamp":1767999178405,"version":"3.49.0"},"reference-count":25,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2016,4,1]],"date-time":"2016-04-01T00:00:00Z","timestamp":1459468800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100001316","name":"ABBOTT Laboratories","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001316","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"NIH","doi-asserted-by":"publisher","award":["HL117933"],"award-info":[{"award-number":["HL117933"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","atherosclerosis-journal.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Atherosclerosis"],"published-print":{"date-parts":[[2016,4]]},"DOI":"10.1016\/j.atherosclerosis.2016.01.028","type":"journal-article","created":{"date-parts":[[2016,1,23]],"date-time":"2016-01-23T02:11:48Z","timestamp":1453515108000},"page":"35-39","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":37,"special_numbering":"C","title":["Fenofibrate, HDL, and cardiovascular disease in Type-2 diabetes: The DAIS trial"],"prefix":"10.1016","volume":"247","author":[{"given":"Fumiyoshi","family":"Tsunoda","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ivor B.","family":"Asztalos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katalin V.","family":"Horvath","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"George","family":"Steiner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ernst J.","family":"Schaefer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bela F.","family":"Asztalos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.atherosclerosis.2016.01.028_bib1","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1093\/ije\/27.4.636","article-title":"Sixteen-year coronary mortality in black and white men with diabetes screened for the multiple risk factor intervention trial (MRFIT)","volume":"27","author":"Vaccaro","year":"1998","journal-title":"Int. J. Epidemiol."},{"issue":"4","key":"10.1016\/j.atherosclerosis.2016.01.028_bib2","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1056\/NEJM199807233390404","article-title":"Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction","volume":"339","author":"Haffner","year":"1998","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.atherosclerosis.2016.01.028_bib3","doi-asserted-by":"crossref","first-page":"S27","DOI":"10.1016\/0021-9150(94)05373-Q","article-title":"The dislipoproteinaemias of diabetes","volume":"110","author":"Steiner","year":"1994","journal-title":"Atherosclerosis"},{"issue":"20","key":"10.1016\/j.atherosclerosis.2016.01.028_bib4","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1056\/NEJM198711123172001","article-title":"Helsinki heart study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease","volume":"317","author":"Frick","year":"1987","journal-title":"N.\u00a0Engl. J. Med."},{"issue":"6","key":"10.1016\/j.atherosclerosis.2016.01.028_bib5","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1056\/NEJM199908053410604","article-title":"Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. veterans affairs high-density lipoprotein cholesterol intervention trial study group","volume":"341","author":"Rubins","year":"1999","journal-title":"N.\u00a0Engl. J. Med."},{"issue":"12","key":"10.1016\/j.atherosclerosis.2016.01.028_bib6","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.1001\/jama.285.12.1585","article-title":"VA-HIT study group. veterans affairs high-density lipoprotein intervention trial. relation of gemfibrozil treatment and lipid levels with major coronary events: VA-HIT: a randomized controlled trial","volume":"285","author":"Robins","year":"2001","journal-title":"JAMA"},{"issue":"22","key":"10.1016\/j.atherosclerosis.2016.01.028_bib7","doi-asserted-by":"crossref","first-page":"2597","DOI":"10.1001\/archinte.162.22.2597","article-title":"Diabetes, plasma insulin, and cardiovascular disease: subgroup analysis from the department of veterans affairs high-density lipoprotein intervention trial (VA-HIT)","volume":"162","author":"Rubins","year":"2002","journal-title":"Arch. Intern Med."},{"issue":"10","key":"10.1016\/j.atherosclerosis.2016.01.028_bib8","doi-asserted-by":"crossref","first-page":"2185","DOI":"10.1161\/01.ATV.0000183727.90611.4f","article-title":"Value of high-density lipoprotein (HDL) subpopulations in predicting recurrent cardiovascular events in the veterans affairs hdl intervention Trial","volume":"25","author":"Asztalos","year":"2005","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"issue":"1","key":"10.1016\/j.atherosclerosis.2016.01.028_bib9","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.metabol.2007.08.009","article-title":"Relation of gemfibrozil treatment and high-density lipoprotein subpopulation profile with cardiovascular events in the veterans affairs high-density lipoprotein intervention Trial","volume":"57","author":"Asztalos","year":"2008","journal-title":"Metabolism"},{"issue":"9260","key":"10.1016\/j.atherosclerosis.2016.01.028_bib10","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1016\/S0140-6736(00)04209-4","article-title":"Effect of fenofibrate on progression of coronary-artery disease in type 2 diabetes: the diabetes atherosclerosis intervention study, a randomised study","volume":"357","author":"Diabetes Atherosclerosis Intervention Study investigators","year":"2001","journal-title":"Lancet"},{"issue":"12","key":"10.1016\/j.atherosclerosis.2016.01.028_bib11","doi-asserted-by":"crossref","first-page":"2670","DOI":"10.1161\/01.ATV.20.12.2670","article-title":"Distribution of ApoA-I-containing HDL subpopulations in patients with coronary heart disease","volume":"20","author":"Asztalos","year":"2000","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.atherosclerosis.2016.01.028_bib12","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/0005-2760(93)90253-6","article-title":"Two-dimensional electrophoresis of plasma lipoproteins: recognition of new apo A-I-containing subpopulations","volume":"1169","author":"Asztalos","year":"1993","journal-title":"Biochim. Biophys. Acta\u2013Lipids Lipid Metab."},{"issue":"1","key":"10.1016\/j.atherosclerosis.2016.01.028_bib13","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1111\/j.2517-6161.1995.tb02031.x","article-title":"Controlling the false discovery rate: a practical and powerful approach to multiple testing","volume":"57","author":"Benjamini","year":"1995","journal-title":"J.\u00a0R. Stat. Soc. B"},{"issue":"13","key":"10.1016\/j.atherosclerosis.2016.01.028_bib14","doi-asserted-by":"crossref","first-page":"1733","DOI":"10.1161\/01.CIR.0000057982.50167.6E","article-title":"DAIS Group. Relationships between low-density lipoprotein particle size, plasma lipoproteins, and progression of coronary artery disease: the diabetes atherosclerosis intervention study (DAIS)","volume":"107","author":"Vakkilainen","year":"2003","journal-title":"Circulation"},{"issue":"5","key":"10.1016\/j.atherosclerosis.2016.01.028_bib15","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1161\/ATVBAHA.114.303284","article-title":"Small dense low-density lipoprotein-cholesterol concentrations predict risk for coronary heart disease: the atherosclerosis risk in communities (ARIC) study","volume":"34","author":"Hoogeveen","year":"2014","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"issue":"1","key":"10.1016\/j.atherosclerosis.2016.01.028_bib16","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1161\/ATVBAHA.113.302401","article-title":"New automated assay of small dense low-density lipoprotein cholesterol identifies risk of coronary heart disease: the multi-ethnic study of atherosclerosis","volume":"34","author":"Tsai","year":"2014","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"issue":"10","key":"10.1016\/j.atherosclerosis.2016.01.028_bib17","doi-asserted-by":"crossref","first-page":"1701","DOI":"10.1194\/jlr.M200037-JLR200","article-title":"Effects of atorvastatin on the HDL subpopulation profile of coronary heart disease patients","volume":"43","author":"Asztalos","year":"2002","journal-title":"J.\u00a0Lipid Res."},{"key":"10.1016\/j.atherosclerosis.2016.01.028_bib18","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/S0021-9150(02)00149-1","article-title":"Comparing the effects of five different statins on the HDL subpopulation profiles of coronary heart disease patients","volume":"164","author":"Asztalos","year":"2002","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.atherosclerosis.2016.01.028_bib19","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1016\/j.amjcard.2006.09.117","article-title":"Comparison of the effects of high doses of rosuvastatin versus atorvastatin on the subpopulations of high-density lipoproteins","volume":"99","author":"Asztalos","year":"2007","journal-title":"Am. J. Cardiol."},{"issue":"5","key":"10.1016\/j.atherosclerosis.2016.01.028_bib20","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1161\/01.ATV.0000066133.32063.BB","article-title":"Change in alpha1 HDL concentration predicts progression in coronary artery stenosis","volume":"23","author":"Asztalos","year":"2003","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"issue":"1","key":"10.1016\/j.atherosclerosis.2016.01.028_bib21","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1161\/ATVBAHA.107.148817","article-title":"Is there a role for fibrates in the management of dyslipidemia in the metabolic syndrome?","volume":"28","author":"Barter","year":"2008","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"issue":"12A","key":"10.1016\/j.atherosclerosis.2016.01.028_bib22","doi-asserted-by":"crossref","first-page":"28L","DOI":"10.1016\/j.amjcard.2008.09.072","article-title":"Fenofibrate for cardiovascular disease prevention in metabolic syndrome and type 2 diabetes mellitus","volume":"102","author":"Steiner","year":"2008","journal-title":"Am. J. Cardiol."},{"issue":"20","key":"10.1016\/j.atherosclerosis.2016.01.028_bib23","doi-asserted-by":"crossref","first-page":"17982","DOI":"10.1074\/jbc.M212191200","article-title":"Apolipoprotein A5, a crucial determinant of plasma triglyceride levels, is highly responsive to peroxisome proliferator-activated receptor alpha activators","volume":"278","author":"Vu-Dac","year":"2003","journal-title":"J.\u00a0Biol. Chem."},{"issue":"5B","key":"10.1016\/j.atherosclerosis.2016.01.028_bib24","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/0002-9343(87)90873-4","article-title":"Changes in lipoprotein kinetics during therapy with fenofibrate and other fibric acid derivatives","volume":"83","author":"Ginsberg","year":"1987","journal-title":"Am. J. Med."},{"key":"10.1016\/j.atherosclerosis.2016.01.028_bib25","doi-asserted-by":"crossref","first-page":"2181","DOI":"10.1161\/01.ATV.0000146325.93749.a8","article-title":"High-density lipoprotein subpopulation profile and coronary heart disease prevalence in male participants of the framingham offspring study","volume":"24","author":"Asztalos","year":"2004","journal-title":"Arterioscler. Thromb. Vasc. Biol."}],"container-title":["Atherosclerosis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0021915016300272?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0021915016300272?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,6,13]],"date-time":"2024-06-13T23:03:20Z","timestamp":1718319800000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0021915016300272"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,4]]},"references-count":25,"alternative-id":["S0021915016300272"],"URL":"https:\/\/doi.org\/10.1016\/j.atherosclerosis.2016.01.028","relation":{},"ISSN":["0021-9150"],"issn-type":[{"value":"0021-9150","type":"print"}],"subject":[],"published":{"date-parts":[[2016,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Fenofibrate, HDL, and cardiovascular disease in Type-2 diabetes: The DAIS trial","name":"articletitle","label":"Article Title"},{"value":"Atherosclerosis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.atherosclerosis.2016.01.028","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2016 Elsevier Ireland Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}